公开(公告)号：US11427864B2

公开(公告)日：2022-08-30

申请号：US16463820

申请日：2017-11-17

Applicant: Exosome Diagnostics, Inc.

Inventor： Johan Karl Olov Skog ,  Elena Castellanos-Rizaldos ,  Vasisht Tadigotla ,  Dominik Grimm ,  Xuan Zhang ,  Wei Yu

IPC: C12P19/34 ,  C12Q1/6851 ,  C12Q1/6886

Abstract: The present invention relates generally to methods and kits for detecting one or more biomarkers, such as an Epidermal Growth Factor Receptor (EGFR) mutation, e.g., T790M mutation, L858R mutation, one or more exon19 insertions and/or one or more exon19 deletions in the EGFR gene, in a biological sample to aid in diagnosis, prognosis, monitoring, or therapy selection for a disease such as, for example, cancer. The methods and kits are useful in aiding in diagnosis, prognosis, monitoring, or therapy selection for lung cancer, e.g., non-small cell lung cancer (NSCLC).

公开(公告)号：US11891664B2

公开(公告)日：2024-02-06

申请号：US16613298

申请日：2018-05-16

Applicant: Exosome Diagnostics, Inc. ,  The Brigham and Women's Hospital

Inventor： James Hurley ,  Christine Coticchia ,  Robert Kitchen ,  Vasisht Tadigotla ,  Johan Karl Olov Skog ,  Jamil Azzi

IPC: C12Q1/6883 ,  G01N1/28 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  C12Q2600/158 ,  G01N1/28 ,  G01N33/6893 ,  G01N2800/245 ,  G01N2800/347

Abstract: The invention relates generally to the use of microvesicle biomarkers such as nucleic acids, including nucleic acid signatures, and/or proteins for assessing a kidney transplant rejection in a patient. The invention further relates to assessing, and/or to monitoring kidney transplant rejection in patients who have received a renal transplant.

公开(公告)号：US11345957B2

公开(公告)日：2022-05-31

申请号：US16631603

申请日：2018-07-18

Applicant: Exosome Diagnostics, Inc.

Inventor： Robert Kitchen ,  Michael Valentino ,  Johan Skog ,  Vasisht Tadigotla ,  Dalin Chan ,  Sudipto Chakrabortty ,  James Hurley

IPC: C12P19/34 ,  C12Q1/686 ,  C12Q1/6806 ,  C12Q1/6851 ,  C12Q1/6886

Abstract: The present disclosure relates to methods for treating glioblastoma in a subject in need thereof using gene signatures in exosomal RNA derived from the subject. The gene signatures comprise: at least one of FAM229B, ZNF35, CTD-2647L4.4, CABP5, CYP20A1, CEP126, DTX2P1-UPK3BP1-PMS2P11, RP11-507K12.1, KRBA2, CALD1, LRFN1, RP2, SLC2A13, CDKL3, SLC8A3, ANTXR2, TIGD5, AC074289.1 RP11-932O9.7; at least one of tRNA-Lys-CTT-2-2, tRNA-Pro-AGG-2-7, LAMTOR2, RAD51AP1, DENND2A, A1BG, THSD1, CSF1, RP11-332M2.1, ZNF717, ZNF860, ORC6, Clorf50, PSPH, HIST1H4C, CYP2U1, THAP8, TMEM192, NAA20; or at least one of CREBBP, CXCR2 and S100A9. The treatment methods comprise measuring the expression level of at least one of the aforementioned genes in exosomal RNA from a subject and administering to the subject a glioblastoma treatment based on the expression level(s).